Key Segments:
By Component/Product Type
-
Products
-
Services
By Application
-
Biomedical
-
Agriculture
By End User
-
Biotechnology & Pharmaceutical Companies
-
Academic & Government Institutes
-
Contract Research/Manufacturing Organizations
By Technology
-
CRISPR-Cas9
-
Base Editing
-
Prime Editing
-
CRISPR-Cas12/13 & Others
By Delivery Method
-
Viral
-
Non-Viral
Regional Coverage:
North America
-
US
-
Canada
Europe
-
Germany
-
France
-
UK
-
Italy
-
Spain
-
Poland
-
Russia
-
Rest of Europe
Asia Pacific
-
China
-
India
-
Japan
-
South Korea
-
Australia
-
ASEAN Countries
-
Rest of Asia Pacific
Middle East & Africa
-
UAE
-
Saudi Arabia
-
Qatar
-
South Africa
-
Rest of Middle East & Africa
Latin America
-
Brazil
-
Argentina
-
Mexico
-
Colombia
-
Rest of Latin America
Available Customization:
With the given market data, SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report:
-
Detailed Volume Analysis
-
Criss-Cross segment analysis (e.g. Product X Application)
-
Competitive Product Benchmarking
-
Geographic Analysis
-
Additional countries in any of the regions
-
Customized Data Representation
-
Detailed analysis and profiling of additional market players
Frequently Asked Questions
The market includes Thermo Fisher Scientific, CRISPR Therapeutics, Intellia Therapeutics, Beam Therapeutics, Caribou Biosciences, Takara Bio, Merck KGaA, GenScript Biotech, Danaher, Editas Medicine, Mammoth Biosciences, Integrated DNA Technologies, Synthego, Horizon Discovery, Lonza, New England Biolabs, Prime Medicine, and Agilent Technologies.
The main opportunities lie in advancing base and prime editing technologies and in expanding agricultural biotechnology applications of CRISPR-Cas systems.
The key growth factor is expanding clinical pipelines for ex vivo and in vivo gene editing therapies, reinforced by sustained academic and government research funding.
By component, the Products segment dominated the market with approximately 79.80% share in 2025, reflecting sustained demand for reagents, kits, and guide RNA libraries.
North America dominated the market with approximately 44.80% share in 2025, supported by a dense concentration of biopharmaceutical companies and research institutions.
